ARCT

#3502
Arcturus Therapeutics Holdings Inc. Common Stock
8.75 USD
+3.43%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
8.63
8.75
Faixa anual
5.86
24.14
Mudança diária
+3.43%
Mudança mensal
+28.87%
Mudança em 6 meses
-58.90%
Mudança anual
-15.05%
Fechamento anterior
8.46
Abrir
8.64
Bid
Ask
Mínimo
8.63
High
8.75
Volume
22
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 248.7 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.55
Price to sales ratio
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Notícias